Form 4 for SPRO Spero Therapeutics, Inc.
Accepted 2023-02-06 00:00:00 ET · period of report 2023-02-03 · accession 0000899243-23-004039 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-06 | 2023-02-03 | SPRO | Mahadevia Ankit | CEO, Pres, Dir | S - Sale | $1.81 | -12.3K | 797.8K | -2% | -$22.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-03 | S | D | 12,286 | $1.81 | 797,832 | D | — | — | (F2) Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Amount also includes 691,205 RSUs held by the Reporting Person. |